Susan Moore on Adapting a Practice for Oral Oncolytics

May 6, 2011

Susan Moore, RN, MSN

Susan Moore Oncology Nurse Practitioner/Consultant, MCG Oncology on Adapting a Practice for Use of Oral Oncolytics

Susan Moore, RN, MSN, ANP, AOCN®, Oncology Nurse Practitioner/Consultant, MCG Oncology, Chicago, IL on Adapting a Practice for Use of Oral Oncolytics

Related Videos

Guillermo Garcia-Manero, MD

Amer Zeidan, MBBS

Sohail Dhanji, MD

Eric A. Singer, MD

Sia Daneshmand MD

Fred Saad, MD, FRCS

Benjamin H. Lowentritt, MD, FACS

Roger Li, MD

Michael Basin, MD

Andrew Katims, MD, MPH

Related Content

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

Simple Hysterectomy Is Noninferior to Radical Hysterectomy in Low-risk, Early-stage Cervical Cancer

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

Simple Hysterectomy Is Noninferior to Radical Hysterectomy in Low-risk, Early-stage Cervical Cancer

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

Simple Hysterectomy Is Noninferior to Radical Hysterectomy in Low-risk, Early-stage Cervical Cancer

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Related Content

A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Gregory W. Roloff, MD

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

$Obecatagene autoleucel was associated with a 76% complete response (CR)/CR with incomplete count recovery rate in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.$

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

Amer Zeidan, MBBS

Imetelstat Prolongs Transfusion Independence, Increases Hemoglobin in R/R MDS

Simple hysterectomy was found to be noninferior to radical hysterectomy and pelvic node dissection in patients with low-risk, early-stage cervical cancer, according to results of the Canadian Cancer Trials Group CX.5/SHAPE trial.

Simple Hysterectomy Is Noninferior to Radical Hysterectomy in Low-risk, Early-stage Cervical Cancer

Dennis J. Slamon, MD

Addition of Ribociclib to Endocrine Therapy Provides iDFS Benefit in HR+/HER2– Early Breast Cancer

Latest Conference Coverage

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL

Dr Garcia-Manero on Luspatercept in Lower-Risk MDS

Dr Zeidan on Imetelstat in Lower-risk MDS

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.